Alvotech and Teva Settled with Johnson & Johnson for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)
Shots:
- Alvotech & Teva entered into a settlement and license agreement with J&J for AVT04, a proposed biosimilar to Stelara (ustekinumab) in the US. AVT04 can be marketed in the US subject to regulatory approval, no later than Feb 2025
- Teva collaborated with Alvotech in 2020 on AVT04 as part of a strategic partnership that covers five biosimilar candidates in the US while Alvotech is responsible for the development, regulatory, and manufacturing & Teva is responsible for commercialization
- Additionally, J&J has settled its patent infringement lawsuit against Amgen over a proposed ustekinumab biosimilar referencing Stelara where Amgen will be allowed to sell its ustekinumab biosimilar no later than Jan 2025
Ref: Teva | Image: Teva
Related News:- Alvotech and STADA Report EMA Acceptance of MAA for AVT04, a Proposed Biosimilar to Stelara (ustekinumab)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
